Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 308734

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Diabetes Treatment
  • Alzheimer’s disease
  • Disease
  • Proteins
  • Vaccine
  • Diagnostic
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 308734

License Grant
University hereby grants to Licensee and Licensee hereby accepts from University the License.  License shall mean the exclusive worldwide license to practice the Research Technology (as hereinafter defined) for the research, development, manufacture, use and sale of Licensee Products.
License Property
The University has made certain inventions (the Pre-Existing Inventions) with respect to Receptors used in the products.

Patent Application US Serial # 07/551,270 -Novel Receptor-Type Phosphotyrosinc Phosi1hatases
Patent Application US Serial # 07/654,188 – Novel Rcccptor-lype Phospholyrosine PhosEltatases

Research Technology shall mean all University Patents and University Know-How.

Licensee Product shall mean any product for the diagnosis, treatment or prevention of human disease which contains or comprises
              (i)   any Receptor (as hereinafter defined); and/or (ii)  any substance which activates or prevents activation or otherwise modulates activation of a Receptor; and/or (iii) any substance which induces, prevents or otherwise modulates intracellular activity of either the activated or resting Receptor and/or (iv)  any substance otherwise  physically interacts with a Receptor and/or (v)  DNA or RNA encoding any of said substances, including probes, vectors or cells modified to contain such DNA or RNA; provided that an Investigational New Drug (IND) application is filed for such Licensee Product within 4 years from the end of the Research Period.  Licensee Product shall not include any product that is licensed by Licensee from a third party other than MPG,  provided that such product  does not act by activating, preventing activation, or otherwise modulating a Validated Target.

MPG shall mean Max-Planck-1 Institut fur Biochemie, Abteilung Molekularbiologie (Director Prof. Dr. Axel Ullrich), located in Am Klopferspitz 18a, W-8003 Martinsreid, an institute of the Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., located in Residenzstrasse 1a, W-8000 Munchen 2, or any scientist affiliated with Max-Planck-1 Institut fur Biochemie, and/or Garching Intrumente Gesellschaft zur industriellen Nutzung von Forschungsergebnissen m.b.h. located in Koniginstrabe 19, W-8000 Munchen 22.

University Patents shall mean Universitys share in all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor (x) which claim Pre-Existing Inventions and which are identified on Appendix I hereto; or (y) which claim  inventions that are made, in whole or in part, by students or employees of University (including the University Scientist) during the term and in the course of the University Research Project (as hereinafter defined). For the avoidance of doubt, University Patents shall  include any such inventions that are made during the term and in the course of the University Research Project, whether funded by Licensee or by United States government agencies under Section 4( c) hereof.

University Know-How shall mean the Pre-Existing Inventions and any information and materials (including, but not limited to, pharmaceutical, chemical, biological and biochemical products, information, trade secrets, know-how, technical and non-technical data, materials, methods and processes and any drawings, plans, diagrams,  specifications and/or other documents containing such information) discovered, developed or acquired by or on behalf of students or employees of University (including The University Scientist) during the term and in the course of the University Research Project (as hereinafter defined).  For the avoidance of doubt, University Know-How shall include any of the foregoing that are developed during the term and in the course of the University Research Project whether funded by Licensee or by United States government agencies wider Section 4( c) hereof.

Receptor shall mean
(i) receptor tyrosine kinases, intracellular tyrosine kinases, or receptors that directly or indirectly activate non-receptor tyrosine kinases; and/or (ii) receptor serine/threonine kinases, intracellular serine/threonine kinases, or receptors that directly or indirectly activate serine/threonine kinases and/or (iii) receptor tyrosine phosphatases, intracellular tyrosine phosphatases, or receptors that directly or indirectly activate tyrosine phosphatases; and/or (iv) molecules that regulate the signaling of the above receptors.

Field of Use
The field of use is for human diseases relating to the diagnosis, treatment or prevention of these human diseases primarily cancer and diabetes.

The Licensees objective is to discover and develop new classes of small molecule drugs which interact in a specific manner with different members of the tyrosine kinase, serine-threonine kinase and tyrosine phosphatase families of signal transduction pathways.  These pathways are involved in a number of human diseases including cancer and diabetes as well as disorders of the bodys immune defenses and neurological systems.

IPSCIO Record ID: 291175

License Grant
University hereby grants to Israel Corporation and Corporation hereby accepts from University the License. License shall mean the exclusive worldwide license to practice University’s share in the University Research Technology (as hereinafter defined) for the development, manufacture, use and sale of the Licensed Products (as hereinafter defined). At the initiative of Corporation or University, the parties shall consult with each other regarding the prosecution of all patent applications with respect to the University Research Technology. University and Corporation shall assist, and cause their respective employees and consultants to assist, each other in assembling inventorship information and data for the filing and prosecution of patent applications on inventions pertaining to the Research Technology. Corporation shall be entitled to grant sublicenses under the License on terms and conditions in compliance and not inconsistent with the terms and conditions of this Agreement (except that the rate of royalty may be at higher rates than those set forth in this Agreement) (i) to a Corporation Entity or (ii) to other third parties for consideration and in an arms-length transaction.
License Property
Licensed Products shall mean all products, drugs, diagnostic reagents, diagnostic methods, therapeutic agents and therapeutic methods covered by a claim of any unexpired University Patents (as hereinafter defined) which has not been disclaimed or held invalid by a court of competent jurisdiction from which no appeal has been or can be taken.

University Research Technology shall mean all University Patents and all University Know-How.

University Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor
(1)  
which claim Pre-Existing Inventions and which are identified hereto; or
(2)  
which claim inventions that are made, in whole or in part, by students or employees of SAMSF during the term and in the course of the Research Project;  
with the exception of all such patents which are Corporation Patents as hereinafter defined.
U.S. Patent Application Serial No. 08/801,301, filed February 18, 1997 entitled Use if Nekatibub To Prevent Cytotoxic effects of Amyloid Protein by Pappolla.
U.S. Provisional Patent Application Serial No. 60/075,555 filed February 23, 1998 entitled Use of 3-Indol-Proprionic acid by Pappolla
U.S. Provisional Patent Application Serial No. 60/079,349 filed March 25, 1998 entitled Inhibition of Alzheimer of Alzheimer Beta-Fibrillogenesis by Mela Tonm by Pappolla.

Corporation Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor which claim inventions that are made, in whole or in part, by students or employees of Corporation.

Research Technology shall mean all University Patents, University Know-How, Corporation Patents and Corporation Know-How.

Field of Use
Field shall mean research, development and testing within pharmaceutical, biotechnological and diagnostic development programs in the field of Alzheimer’s Disease and other central nervous system and neurodegenerative diseases, and in the field of all other possible utilities for melatonin analogs.

IPSCIO Record ID: 239157

License Grant
Licensor grants to the Israeli Licensee the worldwide right and exclusive license to make, have made, use, lease and sell the Licensed Products and to practice the Licensed Processes for the Field of Use to the end of the term for which the Patent Rights are granted, unless sooner terminated as provided in this Agreement.
License Property
The patents are for Short peptides which selectively modulate the activity of protein tyrosine kinases, and, Short Peptides which selectively modulate the activity of serine/threonine kinases.

KinAce platform represents one of the first practical uses of the genomics database to systematically generate drug candidates that target protein kinases. We use computer programs to analyze genomic data that then enables us to create compounds that aim to regulate kinases.  Protein kinases play a key role in the way cells communicate. When protein kinases give an inappropriate signal, the result is often a disease or other unwanted medical condition. Our KinAce platform uses a proprietary algorithm to identify unique regulatory regions within each kinase.

Field of Use
The Field of Use shall mean the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals.

IPSCIO Record ID: 329687

License Grant
The Swiss Licensor, an international non-profit cancer research organization, grants to Licensee an exclusive license under the Licensed Patent Rights to research, develop, make, have made, import have imported. use. have used, sell, have sold, offer for sale, have offered for sale and otherwise exploit Licensed Products in the Field throughout the world.
License Property
Licensed Product means any products the making, selling, using or importing of which is covered by a Valid Claim of a Licensed Patent Right and is (i) an ALK-1 Receptor Product; (ii) an ALK-1 Antibody Product; (iii) an ALK-2 Receptor Product; (iv) an ALK-3 Receptor Product; (v) an ALK-3 Antibody Product; (vi) an ALK4 Receptor Product; (vii) an ALK-4 Antibody Product (viii) an ALK-5 Receptor Product (ix) an ALK-5 Antibody Product; (x) an ALK-6 Receptor Product; (xi) an ALK-6 Antibody Product.

ALK-1 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-1 receptor, as exemplified by amino acids 1-118 of the human ALK-1 sequence presented in U.S. Patent No. 6,316217, or an active po11ion thereof.

ALK-1 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-1 receptor.

ALK-2 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-2 receptor, as exemplified by amino acids 1-124 of the human ALK-2 sequence presented in C .S. Patent No. 6,316,217 or an active portion thereof.

ALK-3 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-3 receptor, as exemplified by amino acids 1-152 of the human ALK-3 sequence presented in U.S. Patent  6.316,217, or an active portion thereof.

ALK-3 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-3 receptor.

ALK-4 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-4 receptor, as exemplified by amino acids 1-126 of the human ALK-4 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-4 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-4 receptor.

ALK-5 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-5 receptor, as exemplified by amino acids 1-121 of the human ALK-5 sequence presented in U.S. Patent No. 6,316.217, or an active portion thereof.

ALK-5 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-5 receptor.

ALK-6 Receptor Product means any product which is comprised at!east in part of an extracellular domain of an ALK-6 receptor, as exemplified by amino acids 1-122 of the murine ALK-6 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-6 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-6 receptor.

Field of Use
The patent rights relate to the first cloning of the type I activin receptors, as well as the treatment of pancreatic tumors with dalantercept.

IPSCIO Record ID: 291176

License Grant
University hereby grants to Licensee and Licensee hereby accepts from University the License. University reserves the right to use, and to permit other non-commercial entities to use, the Research Technology for educational and research purposes other than conducting clinical trials. No license is granted to Licensee outside of the Field. The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States.  

License shall mean the exclusive worldwide license to practice the Research Technology (as hereinafter defined) for the development, manufacture, use and sale of the Licensed Products (as hereinafter defined) in the Field.

License Property
Licensed Products shall mean any vaccine for the mitigation, prophylaxis or treatment of Alzheimer’s Disease, covered by a claim of any unexpired University Patent (as hereinafter defined) which has not been disclaimed or held invalid by a court of competent jurisdiction from which no appeal can be taken, or which incorporates or is developed using University Know-How.

University Patents shall mean all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor

(1)  
which claim Pre-Existing Inventions and which are identified on hereto; or

(2)  
which claim inventions that are made, in whole or in part, by students or employees of University during the term and in the course of the University Research Project.
6,713,450 – Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits

University Research Project shall mean the investigations at University during the Research Period (as hereinafter defined) into the Field under the supervision of the University Scientist(s) in accordance with the research program, which forms an integral part hereof.

Research Technology shall mean all University Patents and University Know-How.

Field of Use
Field shall mean the prophylaxis, mitigation and/or treatment of Alzheimer’s Disease.

IPSCIO Record ID: 328341

License Grant
Licensor grants
a. an exclusive, worldwide license in the Fields of Use to practice Licensor Technical Information to develop, identify, make, use and sell Product(s); and
b. an exclusive, worldwide license to practice Licensor Technical Information to develop, make, use, license and sell Assays that utilize or incorporate Licensor Technical Information.
License Property
Licensor developed various technologies relating to signal transduction within cells, and Licensor owns all rights, title and interest in and to such technologies, including related patents, patent applications and unpatented technology relating to mammalian cell and/or enzyme- based assays useful in identifying compounds that regulate cellular transduction pathways.

Products shall mean any compound, formulation or composition whose utility is identified using an Assay.

Assay shall mean one or more mammalian cell and/or enzyme-based assays relating to the regulation of cellular transduction pathways, including G protein-coupled and/or tyrosine kinase-coupled receptor signal transduction pathways, which incorporates or utilizes Licensor Technical Information.

The patents include
–  Method and product for regulating cell responsiveness to external signals,
–  Using tyrosine phosphorylation of map kinase and characterization of the components of the map kinase activation pathway as a drug discovery assay system,
–  Product and process for regulating signal transduction pathways, and,
–  Method and product for regulating cell responsiveness to external signals.

Field of Use
The Fields of Use shall mean all agricultural, veterinary and human therapeutic and diagnostic uses for Licensor Technical Information.

Licensee is engaged in the discovery of novel small molecule therapeutics that act on targets in human cell signaling pathways.

IPSCIO Record ID: 279366

License Grant
Licensor hereby grants to Licensee the exclusive worldwide right and license, with the right to sublicense on the terms and conditions set forth, in the Field of Use under the Licensor Patent(s) to make, have made, market, have marketed, use, import, offer for sale, sell and have sold Licensed Product (the License). The License granted hereunder shall be subject to any rights of the U.S. Government, its agencies or authorities under Public Law 96-517 and Public Law 98-620 which may be applicable. Notwithstanding the License granted herein, Licensor shall have the right, subject to Licensees consent, not to be unreasonably withheld, to make and have made Licensed Product(s) for itself and distribution to non-profit organizations for research purposes only, but not for any commercial or other purpose. Nothing in the foregoing sentence shall constitute a grant by Licensee or confer upon Licensor any rights to make or use the Biological Materials.
License Property
Licensor Patent(s) shall mean those United States or foreign patents and/or applications listed hereto as amended and modified from time to time by Licensor is hereby incorporated herein by reference, the inventions disclosed therein, and any divisions, reissues, continuations, continuations-in-part or extensions relating or corresponding thereto, and disclosed in foreign patent application corresponding thereto.

US Application Serial No. 09/546,733  

Biological Materials shall mean the vascular endothelial growth factor-2 gene referred to as “VEGF-2” and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA sometimes referred to as “phVEGF-2” or “pVGI.1(VEGF2)”, together with any Progeny, Derivatives and Modifications therefrom.

Initial Product shall mean a product for the treatment of peripheral diabetic neuropathy that incorporates Biological Materials.

Licensed Product shall mean any product or method in the Field of Use covered by one or more Valid Claims.

Intellectual Property shall mean all intellectual property rights, including (i) United States and other national patents and patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether registered or unregistered and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and data, including formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures.

Field of Use
Field of Use shall mean the use of Biological Materials for treating a peripheral neuropathy, including, without limitation, diabetic neuropathy.

Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased. The peripheral nerves make up an intricate network that connects the brain and spinal cord to the muscles, skin, and internal organs.

IPSCIO Record ID: 311746

License Grant
University grants to Licensee an exclusive, worldwide license under the Licensed Patents in the Field of Use to (a) make, have made, use, offer for Sale, import, and Sell Licensed Products and Licensed Services, and (b) to practice Licensed Methods.

University grants to Licensee a nonexclusive, royalty bearing, worldwide license for Licensed Technical Knowledge to manufacture, have made, use, offer for Sale, import, and Sell Licensed Products and Licensed Services.

License Property
Licensed Patents means (a) the United States and foreign patents and/or patent applications identified; (b) any and all patents issuing from the foregoing; (c) any and all claims of continuation-in-part applications that claim priority to the United States patent applications identified, but only where such claims are directed to inventions disclosed in the manner provided in 35 U.S.C. § 112(a) in the United States patent applications identified, and such claims in any patents issuing from such continuation-in-part applications; (d) any and all foreign patent applications, foreign patents or related foreign patent documents that claim priority to the patents and/or patent applications identified; and (e) any and all divisionals, continuations, reissues, reexaminations, renewals, substitutions, and extensions of the foregoing.

*
United States Provisional Patent Application no. 62/575,858 (abandoned); Compounds, their preparation, related compositions, and uses thereof; Filing date October 23, 2017; University ref. #17036 and #16069.
*
United States Provisional Patent Application no. 62/669,926 (converted); Compounds, their preparation, related compositions, and uses thereof; Filing date May 10, 2018; University ref. #17036 and #16069.
*
PCT Patent Application no. PCT/US19/31885 (pending); Inhibitors of the ras oncoprotein, methods of making, and methods of use thereof; Filing date May 10, 2019; University ref. #17036 and #16069.

Invention(s) means a valuable invention or inventions as described in University Case Nos. 16069 and 17036, was/were developed during the course of research conducted at University by the individuals hereinafter listed in this Agreement.

Licensed Product means any product, material, kit, or other article of manufacture or composition of matter, the making, use, Sale, or offer for Sale, or import of which, absent the license granted pursuant to this Agreement, infringes, induces infringement, or contributes to infringement of a Licensed Patent and/or embodies, contains, uses, is used or made through the use of, or was in whole or part derived from Licensed Technical Information.

Licensed Technical Knowledge means proprietary data and information which are not generally known that are acquired and controlled by ULRF and are provided to Licensee by ULRF in order to practice the Licensed Patents. Technical Knowledge shall be limited only to those proprietary data and information to which ULRF has an ownership or other interest during the term of this Agreement; all to the extent and only to the extent that ULRF has the right to grant licenses or other rights thereunder.

Licensed Service means a service provided using Licensed Products or Licensed Methods, including, without limitation, any such service provided in the form of contract research or other research performed by Licensee on behalf of a third party.

Licensed Method means any process or method, the use or practice of which, absent the license granted pursuant to this Agreement, infringes or contributes to or induces the infringement of a Licensed Patent or relies on Licensed Technical Knowledge.

The University is a research institution for the purpose of promoting and supporting research projects, investigations, and other activities relating to the educational, scientific, literary, artistic, health care and public service missions of the University.

The RAS oncogenes comprise the most frequently mutated class of genes in human cancers, which is why targeting RAS has been fiercely pursued for decades.

Cells can proliferate uncontrollably when hyper-activating mutations occur in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS). These RAS mutations are present in approximately one-third of all cancers, including a high percentage of pancreatic, colorectal and lung cancers. Although drugs that target downstream signaling of RAS are available, they have shown limited clinical activity (most likely because RAS acts like a hub that activates multiple effectors). As such, blocking any single pathway, or even two, typically provides disappointing clinical effect. By contrast, the RAS-F small molecules' intended mechanism of action is to inhibit or block the binding of mutated RAS to their effector proteins, thereby leaving the proteins from mutated RAS unable to cause further harm.

Field of Use
Intellectual property covers the 'RAS-F' family of RAS oncogene protein-protein interaction inhibitor small molecule drug candidates. Licensee will evaluate these patent-pending compounds in order to identify a lead drug candidate for further development against one or more cancers.

Licensee is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.